Anti-Cancer

Midostaurin (TAURITMO CAP) 25MG Tablet

$354.00

TAURITMO Capsule offers a valuable treatment option for patients with FLT3-mutated AML and systemic mastocytosis, providing an effective and well-tolerated therapy to help manage these challenging hematologic malignancies.

Quantity

Midostaurin (TAURITMO CAP) 25MG Tablet quantity

Add to cart

Sku:

354

Tag:

Midostaurin

Description

TAURITMO Capsule contains Midostaurin in a strength of 25mg, serving as a medication primarily prescribed for the treatment of certain types of blood cancers, including acute myeloid leukemia (AML) and systemic mastocytosis (SM).

Key Features:

• Blood Cancer Treatment: TAURITMO Capsule is indicated for the treatment of specific types of blood cancers, including acute myeloid leukemia (AML) and systemic mastocytosis (SM), particularly in patients with specific genetic mutations.
• Midostaurin Mechanism of Action: Midostaurin, the active ingredient in TAURITMO, is a multikinase inhibitor that targets various kinases involved in cell proliferation and survival, including FLT3 (Fms-like tyrosine kinase 3) and KIT, which are commonly mutated in AML and SM, respectively.
• FLT3-Mutated AML: TAURITMO is specifically indicated for use in patients with FLT3-mutated AML, a subtype of AML associated with poor prognosis and increased risk of relapse.
• Systemic Mastocytosis: TAURITMO may also be used for the treatment of aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and mastocytosis with associated hematologic neoplasm (SM-AHN), conditions characterized by abnormal proliferation of mast cells.
• Fixed-Dose Capsule: TAURITMO Capsule contains a fixed dose of Midostaurin (25mg) in each capsule, simplifying dosing and ensuring consistent medication delivery.
• Oral Administration: Administered orally, usually twice daily with food, TAURITMO Capsule offers convenient dosing for patients with blood cancers, allowing them to take their medication at home.
• Combination Therapy: TAURITMO is typically used in combination with standard chemotherapy regimens for AML or as monotherapy for SM, depending on the specific disease characteristics and treatment goals.
• Clinical Efficacy: Clinical studies have demonstrated the efficacy of Midostaurin in improving overall survival and reducing the risk of relapse in patients with FLT3-mutated AML, as well as in achieving clinical responses in patients with systemic mastocytosis.
• Potential Adverse Effects: Common side effects of TAURITMO may include nausea, vomiting, diarrhea, fatigue, and rash. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of TAURITMO as a treatment option for blood cancers should be based on factors such as disease subtype, genetic mutations, patient’s overall health status, and treatment goals.